Notice: This company has been marked as potentially delisted and may not be actively trading. Champions Oncology (CSBR) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrends Get the Latest News and Ratings for CSBR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Champions Oncology and its competitors. Enter your email to sign up for newsletter Sign Up CSBR Analyst Ratings Over TimeTypeCurrent Forecast3/4/24 to 3/4/251 Month Ago2/3/24 to 2/2/253 Months Ago12/5/23 to 12/4/241 Year Ago3/5/23 to 3/4/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.00$8.00$6.00$7.50Forecasted Upside-21.42% Downside-27.19% Downside41.18% Upside32.98% UpsideConsensus RatingBuyBuyBuyModerate Buy CSBR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History CSBR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Champions Oncology Stock vs. The CompetitionTypeChampions OncologyMedical CompaniesS&P 500Consensus Rating Score 3.00 2.82 2.53Consensus RatingBuyModerate BuyModerate BuyPredicted Upside-22.71% Downside22,697.44% Upside17.90% UpsideNews Sentiment RatingPositive NewsSee Recent CSBR NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails12/12/2024Craig Hallum2 of 5 starsM. HewittSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost TargetBuy ➝ Buy$6.00 ➝ $8.00+36.99%9/22/2023Roth Mkm2 of 5 stars Lower TargetBuy ➝ Buy$9.00 ➝ $7.50+40.71%3/16/2023Benchmark2 of 5 stars DowngradeBuy ➝ HoldAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:27 PM ET. CSBR Forecast - Frequently Asked Questions What is Champions Oncology's forecast for 2025? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Champions Oncology is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. Should I buy or sell Champions Oncology stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CSBR shares. Does Champions Oncology's stock price have much downside? According to analysts, Champions Oncology's stock has a predicted downside of -21.42% based on their 12-month stock forecasts. What analysts cover Champions Oncology? Champions Oncology has been rated by research analysts at Craig Hallum in the past 90 days. Do Wall Street analysts like Champions Oncology more than its competitors? Analysts like Champions Oncology more than other "medical" companies. The consensus rating for Champions Oncology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CSBR compares to other companies. Stock Forecasts and Research Tools Related Companies Valneva Stock Forecast Sana Biotechnology Stock Forecast Relay Therapeutics Stock Forecast MeiraGTx Stock Forecast Immatics Stock Forecast Maze Therapeutics Stock Forecast Cullinan Therapeutics Stock Forecast Autolus Therapeutics Stock Forecast Ginkgo Bioworks Stock Forecast Humacyte Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:CSBR) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSBR Stock Alerts